New Findings on Weight Loss Drugs and Heart Health
Recent research suggests that weight loss medications could significantly lower the risk of hospitalization or early death for heart patients, potentially by half. These findings come from the largest study of its type to date, involving GLP-1 agonists—drugs initially designed to manage diabetes.
Presenting these results at the major heart conference in Madrid, researchers highlight the “dramatic benefits” for heart patients, indicating that millions could soon benefit from these treatments to improve their health and longevity.
These medications mimic the glucagon-like peptide (GLP) 1 hormone, which helps control appetite and triggers a feeling of fullness. Initially targeted toward diabetes treatment, recent studies have shown they might have life-saving potential for various other health conditions beyond obesity.
In this specific study, led by researchers from Mass General Brigham in Boston, data from over 90,000 obese heart failure patients with type 2 diabetes was analyzed. All participants experienced heart failure with preserved ejection fraction (HFpEF), which is the most prevalent form of this condition.
The study revealed that those taking semaglutide experienced a 42% reduction in the likelihood of hospitalization or early death compared to a placebo group. Notably, another drug, tirzepatide, demonstrated an even greater impact, decreasing the risk by 58%.
Over 60 million people globally are affected by heart failure. Previous smaller studies hinted that weight-loss medications could alleviate heart failure symptoms, but this is the first time such effects have been assessed in a large population concerning serious outcomes like hospitalization and mortality.
The findings were published simultaneously in JAMA, a prominent medical journal. Dr. Nils Krüger from Brigham and Women’s Hospital emphasized the limited treatment options currently available for HFpEF. He noted that while semaglutide and tirzepatide are recognized for their weight loss and blood sugar control, the study indicates that they may also significantly benefit patients struggling with both obesity and type 2 diabetes by reducing serious heart failure outcomes.
There’s potential for GLP-1 medications to fill a critical gap in treating heart failure in the future, according to Krüger. These advancements align with previous studies showing that weight loss drugs might help in preventing heart conditions too. For instance, a recent trial indicated that semaglutide users had a 20% lower chance of experiencing heart attacks, strokes, or deaths related to cardiovascular disease.
Dr. Carlos Aguiar, the vice-president of the European Society of Cardiology, expressed optimism about the findings. He pointed out that the results indicate a clear benefit from using semaglutide or tirzepatide to lower hospitalization risks for heart failure or overall mortality. Aguiar noted that while there are still uncertainties about the broader efficacy of these treatments, their effects extend beyond merely causing weight loss, potentially leading to reduced hospital visits and fatalities for heart failure patients.
Despite the encouraging results, Aguiar called for additional evidence before health professionals can confidently prescribe these weight loss drugs specifically to mitigate risks related to heart failure. Nonetheless, he recognized it as a positive step forward.
Dr. Sonya Babu-Narayan, a consultant cardiologist and clinical director at the British Heart Foundation, underscored that these findings contribute to an expanding body of evidence that supports the use of weight loss drugs for those dealing with both obesity and heart failure. She stressed the importance of ensuring eligible heart patients have access to these therapies alongside established heart failure treatments.
